<SEC-DOCUMENT>0001209191-18-020187.txt : 20180316
<SEC-HEADER>0001209191-18-020187.hdr.sgml : 20180316
<ACCEPTANCE-DATETIME>20180316163143
ACCESSION NUMBER:		0001209191-18-020187
CONFORMED SUBMISSION TYPE:	4/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20171229
FILED AS OF DATE:		20180316
DATE AS OF CHANGE:		20180316

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			SCHEINBERG DAVID A
		CENTRAL INDEX KEY:			0001250316

	FILING VALUES:
		FORM TYPE:		4/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		18696012

	MAIL ADDRESS:	
		STREET 1:		325 CENTRAL PARK W
		STREET 2:		APT 38
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10025

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELLAS Life Sciences Group, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		315 MADISON AVENUE
		STREET 2:		4TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		(813) 864-4523

	MAIL ADDRESS:	
		STREET 1:		315 MADISON AVENUE
		STREET 2:		4TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galena Biopharma, Inc.
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922
</SEC-HEADER>
<DOCUMENT>
<TYPE>4/A
<SEQUENCE>1
<FILENAME>doc4a.xml
<DESCRIPTION>FORM 4/A SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4/A</documentType>

    <periodOfReport>2017-12-29</periodOfReport>

    <dateOfOriginalSubmission>2017-12-29</dateOfOriginalSubmission>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001390478</issuerCik>
        <issuerName>SELLAS Life Sciences Group, Inc.</issuerName>
        <issuerTradingSymbol>SLS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001250316</rptOwnerCik>
            <rptOwnerName>SCHEINBERG DAVID A</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O SELLAS LIFE SCIENCES GROUP, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>315 MADISON AVENUE, 4TH FLOOR</rptOwnerStreet2>
            <rptOwnerCity>NEW YORK</rptOwnerCity>
            <rptOwnerState>NY</rptOwnerState>
            <rptOwnerZipCode>10017</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2017-12-29</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>9107</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>9107</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">In connection with the merger of SELLAS Life Sciences Group, Ltd (&quot;SELLAS&quot;) and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the &quot;Merger&quot;), outstanding restricted stock units (&quot;RSUs&quot;) to be settled in SELLAS common shares were assumed by the Issuer and will be settled in shares of the Issuer's common stock based on the following exchange ratio: 43.9972 shares of the Issuer's common stock for each common share of SELLAS.</footnote>
        <footnote id="F2">Represents shares issuable upon vesting of RSUs. The RSUs are subject to, and to vest must satisfy, both (a) performance-based vesting restrictions (the RSUs will satisfy the performance-based vesting restrictions upon a liquidity event as defined in the award agreement) and (b) time-based vesting restrictions (100% of the RSUs satisfied the time-based vesting restrictions on February 27, 2018). The Merger did not constitute a liquidity event for the performance-based vesting restrictions.</footnote>
    </footnotes>

    <remarks>This Amendment to Form 4 (originally filed on December 29, 2017) is being filed solely to correct information contained in footnote 2.</remarks>

    <ownerSignature>
        <signatureName>David A. Scheinberg, by /s/ Ron A. Metzger, Attorney-in-Fact</signatureName>
        <signatureDate>2018-03-15</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
